Part C: Malignant Mesothelioma
1 clinical trials · Condition
◉ Watch Part C: Malignant Mesothelioma
| Record | Firm | Date |
|---|---|---|
| Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma (NCT02141347) | AstraZeneca | 2014-05-22 |
Track Part C: Malignant Mesothelioma automatically
Every clearance here is in the API, with alerts when new ones post.